EUVIMEDEUVIMED entdecken
Crossref

Vanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek)

CDA-AMC

Canadian Journal of Health Technologies · 12.03.2026 · 6 (3)

DOI: 10.51731/cjht.2026.1378 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 12.03.2026. Verfasst von CDA-AMC.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses vanzacaftor/tezacaftor/deutivacaftor (Alyftrek)Oral tablets:Vanzacaftor 4 mg/tezacaftor 20 mg/deutivacaftor 50 mgVanzacaftor 10 mg/tezacaftor 50 mg/deutivacaftor 125 mg Indication: For the treatment of cystic fibrosis in patients aged 6 years and older who have at least 1 F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Zitieren

APA

CDA-AMC (2026). Vanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek). Canadian Journal of Health Technologies, 6(3). https://doi.org/10.51731/cjht.2026.1378

Vancouver

CDA-AMC. Vanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek). Canadian Journal of Health Technologies. 2026;6(3). doi:10.51731/cjht.2026.1378

BibTeX
@article{CDAAMC2026,
  author = {CDA-AMC},
  title = {Vanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek)},
  journal = {Canadian Journal of Health Technologies},
  year = {2026},
  volume = {6},
  number = {3},
  doi = {10.51731/cjht.2026.1378}
}
Kostenlos starten →